piRNA-823 is a novel potential therapeutic target in aortic dissection

Pharmacol Res. 2023 Oct:196:106932. doi: 10.1016/j.phrs.2023.106932. Epub 2023 Sep 20.

Abstract

Aortic dissection (AD) presents a medical challenge for clinicians. Here, to determine the role of a novel small non-coding piRNA-823 (piR-823) in AD, murine and human aorta from patients with AD were used. A high expression levels of piR-823 were found in patients with AD. Using performed loss- and gain-of-function assays in vitro and in vivo, we explore the regulatory effect of piR-823 on vascular smooth muscle cells (VSMCs) and AD. piR-823 obviously facilitates the proliferation, migration, and phenotypic transformation of VSMCs with or without nicotine treatment. piR-823 directly binds and suppresses histone deacetylase 1 (HDAC1) expression, and regulates the acetylation of histone 3 (H3) via H3K9ac and H3K27ac, eventually, VSMC functions and AD. To consolidate our findings, AD murine model was performed, and we observed that piR-823 antagomir strongly inhibited the pathogenesis of AD through regulating vascular remodeling. Thus, our study finds a potential target for the prevention and treatment strategy for nicotine-induced AD.

Keywords: Acetylation; Aortic dissection; Vascular remodelling; Vascular smooth muscle cells; piR-823.

MeSH terms

  • Animals
  • Aorta
  • Aortic Dissection* / drug therapy
  • Aortic Dissection* / genetics
  • Cell Proliferation
  • Cells, Cultured
  • Humans
  • Mice
  • Myocytes, Smooth Muscle / metabolism
  • Nicotine / pharmacology
  • Piwi-Interacting RNA*

Substances

  • Piwi-Interacting RNA
  • Nicotine